Radical Proposal For Reorganizing Research Support: Lotteries, Prizes

It's hard to escape the sense of concern in the scientific community that something has gone awry with the mechanisms by which public funds are allocated for research. Before putting forth several proposals for change in the current arrangement, I feel it is important to point out certain realities--moral hazards, perhaps--that must be taken into consideration by anyone presuming to tamper with the status quo: * A robust government demands answers for the investment of public wealth, whereas a

Written byJack Sommer
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

* A robust government demands answers for the investment of public wealth, whereas a healthy scientific research effort will measure success by generating some answers and a lot more questions.

* The public must be able to ascertain what it gets for its investment more swiftly than most research projects require for their completion; and elected representatives of the public naturally want to show results for their supportive votes.

* The resulting tension between scientists and policymakers cannot be resolved: Public representatives in legislatures want tangible results, which are the product of technology rather than the direct product of science; public servants in the science bureaus try to balance competing demands and avoid mistakes.

Given the hazards, my suggested correctives are delivered in the hope that while they will not quickly resolve past negative consequences of public endowments, they might diminish their continued generation. They are geared to support advances ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies